Single-agent gemcitabine in patients with resistant small-cell lung cancer

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 557-561

  Van Der Lee, I ^a   Smit, E F ^b   Van Putten, J W G ^c   Groen, H J M ^c   Schlosser N J J ^d   Postmus, P E ^b   Schramel, F M N H ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d St Antonius Hospital ^*

Author keywords

Gemcitabine; Resistant; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FEVER; DRUG RESPONSE; DYSPNEA; EVALUATION; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; STATISTICS; THROMBOCYTOPENIA; TIME; TOXICITY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; DRUG RESISTANCE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034997001     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011104509759     Document Type: Article

References (20)

1. Bunn PA Jr, Carney DN. Overview of chemotherapy for small-cell lung cancer. Semin Oncol 1997; 24 (2, Suppl 7): 69-74.
2. Chute JP, Chen T, Feigal E et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 1999; 17: 1794-801.
3. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-24.
4. Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small-cell lung cancer. Cancer Treat Rev 1999; 25: 199-206 (Review).
5. Ihde DC, Glatstein EJ, Pass HI. Small-cell lung cancer. In DeVita VT Jr. Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, fifth edition. Philadelphia, Pennsylvania: Lippincott-Raven 1997; 911-50.
6. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15: 2090-6.
7. Smit EF, Fokkema E, Biesma B et al. A phase II study of paelitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77: 347-51.
8. Groen HJ, Fokkema E, Biesma B et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule. J Clin Oncol 1999; 17: 927-32.
9. Cormier Y, Eisenhauer E, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283-5.
10. National Cancer Institute. Guidelines for Reporting Adverse Reactions. Bethesda, Maryland: Division of Cancer Treatment, National Cancer Institute 1988.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
12. Grant SC, Gralla RJ, Kris MG et al. Single-agent chemotherapy trials in small-cell lung cancer, 1970 1990: The case for studies in previously treated patients. J Clin Oncol 1992; 10: 484-98.
13. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429-35.
14. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23 (5, Suppl 10): 32-5 (Review).
15. Hansen HH, Sorensen JB. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: A review. Semin Oncol 1997; 24 (2, Suppl 7): 38-41.
16. Andersen H, Lund B. Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-6.
17. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-40.
18. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung canter: A multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-8.
19. Perez-Soler R, Glisson BS, Lee JS et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14: 2785-90.
20. Groen HJ, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second-line treatment for recurrent or progressive brain metastases from small-cell lung cancer. Eur J Cancer 1993; 29A: 1696-9.